251: Bancel v. Bernie, Sarepta's FDA runaround, & Regeneron's ever-growing blockbuster
b"We discuss the theatrical merits and actual implications of Moderna CEO St\\xe9phane Bancel's appearance before a committee led by Sen. Bernie Sanders. We also talk about the latest news in the life sciences, including Regeneron Pharmaceuticals' latest data for its powerhouse drug Dupixent, an about-face for Sarepta Therapeutics, and how the FDA appears to view biomarkers in neurological diseases."